Abstract:The antigenic relationship of 9 flaviviruses, Yellow fever (YF), Wesselsbron (WSL), Uganda S (UGS), Potiskum (POT), West Nile (WN), Banzi (BAN), Zika (ZK), Dengue type 1 (DEN-1) and Dengue type 2 (DEN-2), was assessed by cross-haemagglutination-inhibition (Cross-HI) and cross-complement fixation (Cross-CF) reactions between each of the viruses and their homologous immune mouse ascitic fluids. Titre ratios were calculated using the heterologous and homologous titres. Cross-CF reactions revealed wider antigenic … Show more
“…Generally, a range of R-values ≤ 0.5 or ≥ 2 is an indication that there is a significant antigenic difference between two strains (Baba et al, 1998). In this report, 48.71% of heterologous reactions fall within this range.…”
A AB BS ST TR RA AC CT TThe antigenic properties of thirteen isolates of Newcastle disease virus were assessed against La Sota strain. Using one of the previously recognized formulas significant antigenic differences were observed and marked inhibitory activities were noticed amongst the isolates and their hyper-immune sera as well as that of the La Sota strain. The implications of these differences for Newcastle disease epidemiology and control in Nigeria are discussed.Key words: vaccine virus, wild virus, Newcastle disease, Nigeria.
R RE ES SU UM MO OAs propriedades antigênicas de treze isolados do vírus da doença de Newcastle foram comparados com amostras La Sota. Usando uma das fórmulas previamente reconhecidas, significantes diferenças antigênicas foram observadas e marcantes atividades inibitórias foram percebidas entre os isolados e seus soros hiperimunes, bem como das amostras La Sota. As implicações destas diferenças para a epidemiologia e controle da Doença de Newcastle na Nigéria são discutidos.Palavras-chave: vírus vacinal, vírus selvagem, doença de Newcastle, Nigéria.
“…However, of the 96 recovered donors, only 37 (38.5%) were positive to HCV genome detection, and more than 60% of the anti-HCV positive individuals had no viremia. The presence of specific antibodies against HCV and absence of HCV-RNA is a common finding and may be related with one of the following causes: a) the patient has resolved the infection eliminating the virus, b) the infection is so recent and there is no sufficient viral load to detect the virus and the patient should be continuously monitored, or c) there is a cross reaction with antibodies different from anti-HCV [17-21]. …”
BackgroundWorldwide, 130 million persons are estimated to be infected with HCV. Puebla is the Mexican state with the highest mortality due to hepatic cirrhosis. Therefore, it is imperative to obtain epidemiological data on HCV infection in asymptomatic people of this region. The objective of present study was to analyze the prevalence of antibodies and genotypes of hepatitis C virus (HCV) in blood donors from Puebla, Mexico.ResultsThe overall prevalence was 0.84% (515/61553). Distribution by region was: North, 0.86% (54/6270); Southeast, 1.04% (75/7197); Southwest, 0.93% (36/3852); and Central, 0.79% (350/44234). Ninety-six donors were enrolled for detection and genotyping of virus, from which 37 (38.5%) were HCV-RNA positive. Detected subtypes were: 1a (40.5%), 1b (27.0%), mixed 1a/1b (18.9%), undetermined genotype 1 (5.4%), 2a (2.7%), 2b (2.7%), and mixed 1a/2a (2.7%). All recovered donors with S/CO > 39 were HCV-RNA positive (11/11) and presented elevated ALT; in donors with S/CO < 39 HCV-RNA, positivity was of 30.4%; and 70% had normal values of ALT. The main risk factors associated with HCV infection were blood transfusion and surgery.ConclusionsHCV prevalence of donors in Puebla is similar to other Mexican states. The most prevalent genotype is 1, of which subtype 1a is the most frequent.
scite is a Brooklyn-based startup that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.